Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
(Unit: KRW in millions)
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in millions)
| Item | 2021 | 2022 | 2023 |
|---|---|---|---|
| Operating profit | -1,555 | -4,938 | -4,762 |
| Other gains | 2 | 1 | 7 |
| Other losses | 96 | 113 | 2,946 |
| Finance costs | 957 | 1,659 | 2,693 |
| Finance income | 190 | 9,405 | 4,938 |
| Cost Of Sales | 5,013 | 3,113 | 3,218 |
| Net profit | -2,664 | 2,696 | -5,432 |
| Sales | 11,840 | 10,632 | 10,472 |
(Unit: KRW in millions)
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in millions)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Total Assets | 20,959 | 31,018 | 28,093 |
| Current Assets | 8,672 | 14,123 | 13,417 |
| Non-current Assets | 12,287 | 16,895 | 14,676 |
| Total equity | 5,106 | 16,185 | 10,847 |
| Capital surplus | 18,293 | 27,257 | 27,257 |
| Share capital | 3,847 | 4,570 | 4,570 |
| Retained earnings | -16,270 | -13,574 | -16,431 |
| Current liabilities | 12,626 | 11,793 | 12,990 |
| Total liabilities | 15,854 | 14,833 | 17,246 |
| Non-Current liabilities | 3,228 | 3,040 | 4,256 |